SLC5A2 and type 2 diabetes mellitus: In this Taiwan nationwide cohort study, there was a significant 11% risk reduction in the incidence of gout in 47 405 patients with type 2 diabetes who received an SGLT2 inhibitor compared with 47 405 propensity score–matched individuals receiving dipeptidyl peptidase 4 inhibitors, particularly for patients using dapagliflozin.